Targeted Oncology Staff

During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what challenges the referral process poses.

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for repotrectinib in non–small cell lung cancer.

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for chronic lymphocytic leukemia.

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of multiple myeloma after quadruplet frontline with transplant.

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

During a Case-Based Roundtable® event, Elizabeth M. Wulff-Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal cell carcinoma.

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary refractory or early relapsed DBLCL since the introduction of CAR T-cell therapy.

Nam Quoc Bui, MD, discusses survival, symptom control, and ovarian toxicity in the DeFi trial of nirogacestat in patients with desmoid tumors.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population.

In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering the recent data from the ARANOTE study.

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder cancer.

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.

In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first article of a 2-part series.

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their approaches.

During a Case-Based Roundtable® event, Jay Yang, MD, discussed the trial comparing luspatercept with ESA in myelodysplastic syndrome.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in metastatic melanoma and when to stop therapy.

Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment.

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON trials of immunotherapy in patients with metastatic non–small cell lung cancer.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after acalabrutinib and venetoclax/rituximab.

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which combination therapy to use for a patient with metastatic renal cell carcinoma.

During a live event, Nam Quoc Bui, MD discussed desmoid tumors, their presentation, and treatment.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to CAR T-cell therapy in multiple myeloma.

During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for myelofibrosis in the second of 2 articles.

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.